CHRS today
$0.54-$0.04 (-7.55%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minSymmetric Triangle
Daily trend turns down below $0.71
Key levels
Resistance$0.89
Resistance$0.75
Latest news & SEC filings
DealOncolytics Biotech, Coherus Oncology strike pact to supply anal cancer trial
EarningsCoherus Oncology releases Q3 2026 numbers, sets strategic prioritization plan
AnalystGuggenheim keeps Buy rating on Coherus Oncology, cuts target to $8
All CHRS news →About Coherus Oncology
Coherus Oncology is a commercial-stage oncology company focused on immuno-oncology therapies. Its approved product, LOQTORZI, is a PD-1 inhibitor used to treat nasopharyngeal carcinoma in the United States, where the company also sells it through specialty distributors. The company is developing two clinical-stage antibody candidates, casdozokitug and tagmokitug, and holds global development and commercialization rights to them.
Based on the company's 10-K filed Mar 9, 2026.
Nasdaq · Healthcare
Coherus Oncology, Inc. (CHRS)
What Is the Price Target for CHRS?
SEPT Low Target
$7.00
SEPT Mid Target
$7.00
SEPT High Target
$7.00
Analyst Consensus
$7.00
Is CHRS a Buy or Sell Right Now?
Thesis
- •Revenue growing 59.8% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CHRS.
Start Free Trial →Is CHRS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$5.49
17
Moat Score
NONE
5/9
Piotroski Score
-9.1
Altman Z-Score
What Is Smart Money Doing with CHRS?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Satvat Ali J. | director | Buy | 30,000 | - | Jun 5, 2026 |
| Karachun Rita A | director | Buy | 30,000 | - | Jun 5, 2026 |
| Newcomer Lee Nisley | director | Buy | 30,000 | - | Jun 5, 2026 |
| Ryan Michael Lee | director | Buy | 30,000 | - | Jun 5, 2026 |
| O'Donnell-Tormey Jill | director | Buy | 30,000 | - | Jun 5, 2026 |
| Wahlstrom Mats | director | Buy | 30,000 | - | Jun 5, 2026 |
| Newton Charles W. | director | Buy | 30,000 | - | Jun 5, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CHRS Growth Story
Revenue YoY
59.8%
3yr Revenue CAGR
-41.5%
EPS Growth YoY
472%
FCF Growth YoY
N/A%
Revenue Trend
ACCELERATING
Dark Pool Trades for CHRS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CHRS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:46:46 | $0.55 | 1,275 | $$700 | SELL |
| 20:59:36 | $0.54 | 1,500 | $$805 | SELL |
| 20:59:35 | $0.54 | 2,000 | $$1K | BUY |
| 20:59:32 | $0.54 | 2,000 | $$1K | BUY |
| 20:58:48 | $0.54 | 2,000 | $$1K | BUY |
5 dark pool trades shown · $$5K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for CHRS
PREVIEWSEPT Investing provides real-time options flow tracking for CHRS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $1.5 | Feb 19 | 99 | $$15 | 3 | SWEEP |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About CHRS
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for CHRS. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $CHRS (Coherus Oncology, Inc.) Price: $11.13 | Zone: $10.91 to $11.23 Conviction: LOW | Analyst upside: +710.8% Near resistance (69% of range) — breakout watch. No recent news — techni...
Join 3,500+ traders discussing CHRS in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Coherus Oncology, Inc. (CHRS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CHRS — frequently asked questions
What is CHRS stock price today?
Coherus Oncology, Inc. (CHRS) is at $0.54, down 7.55% (-$0.04) at the Nov 12, 2026 close.
Why is CHRS stock moving today?
Latest CHRS news — Nov 12, 2026: Oncolytics Biotech, Coherus Oncology strike pact to supply anal cancer trial · Nov 10, 2026: Coherus Oncology releases Q3 2026 numbers, sets strategic prioritization plan
What is the CHRS price target?
The average analyst price target for CHRS is $7.00, ranging from $7 to $7, based on 1 analysts.
What do analysts rate CHRS?
Analyst ratings for CHRS: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did CHRS beat earnings?
CHRS last reported on Aug 5, 2026: EPS -$0.19 vs -$0.25 expected — a beat of 24.0%.
Does CHRS pay a dividend?
CHRS does not currently pay a dividend.
What are CHRS support and resistance levels?
Resistance: $0.75, $0.89, $1.06.
What are insiders doing with CHRS?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on CHRS?
Nov 12, 2026: Oncolytics Biotech, Coherus Oncology strike pact to supply anal cancer trial · Nov 10, 2026: Coherus Oncology releases Q3 2026 numbers, sets strategic prioritization plan · Nov 10, 2026: Guggenheim keeps Buy rating on Coherus Oncology, cuts target to $8